Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Chong Kun Dang Tofacitinib vs XELJANZ in Healthy Volunteers
NCT03868072Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Feb 2019
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tofacitinib oral solution in rheumatoid arthritis (RA) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve from time zero to last quantifiable concentration at 12 hours and Maximum Plasma Concentration at 12 hours. Started Feb 2019; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03868072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03868072.